|Bid||6.75 x 4000|
|Ask||7.17 x 2200|
|Day's Range||6.78 - 7.17|
|52 Week Range||4.81 - 8.65|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||18.15|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at two upcoming conferences. The management team will also host one-on-one investor meetings
Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) shareholders might be concerned after seeing the share price drop 14% in...
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?